Samsung applies Europe approval of ‘SB5,’ third biosimilar
On the 18th, Samsung Bioepis(CEO Han-seung Ko) announced application of the sales approval of the ‘Humira’ biosimilar, ‘SB5,’ to the EMA(European Medicines Agency).
SB5, the Samsung Bioepis’s third biosimilar product, is a U.S. Abbbies’s Humira biosimilar which recorded approximately KRW 16 tril...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
